Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Kaposi 1Lymphoma 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Valganciclovir 3Paclitaxel 3Nelfinavir 3Bevacizumab 3pembrolizumab 2Zidovudine 2Semaxinib 2Ritonavir 2Propranolol 2Nivolumab 2Interferon alpha-2 2Indinavir 2Filgrastim 2Etoposide 2Doxorubicin 2vesnarinone 1tocilizumab 1tin etiopurpurin 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1talimogene laherparepvec 1nirogacestat 1liposomal doxorubicin 1lenvatinib 1ixazomib 1halofuginone 1etoposide phosphate 1daromun 1Vincristine 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Kaposi × Didanosine × Clear all
NCT00001114 2021-11-01

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
90 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡